Jane Elizabeth Scanlon

USPTO Granted Patents = 5 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 7.9

ph-index = 4

Forward Citations = 54(Granted Patents)

Location History:

Sawston, GB (2011 - 2013)
Cambridge, GB (2013 - 2014)

Company Filing History:

4 out of 262

Cancer Research Technology Limited

Years Active: 2011-2014

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8785457 - Pyrimidine derivatives as mTOR inhibitors (2014-07-22),

2. 8618121 - 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors (2013-12-31),

3. 8530468 - Bicyclylaryl-aryl-amine compounds and their use (2013-09-10),

4. 8367658 - Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use (2013-02-05),

5. 8058045 - Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use (2011-11-15),

Title: The Innovative Contributions of Jane Elizabeth Scanlon

Introduction

Jane Elizabeth Scanlon, based in Cambridge, GB, is a distinguished inventor recognized for her innovative contributions to pharmaceutical compounds. With a total of five patents to her name, she has made significant strides in the field of medicinal chemistry, focusing on inhibitors that target critical cellular functions.

Latest Patents

Among her latest innovations, Scanlon has developed pyrimidine derivatives as mTOR inhibitors. This invention relates to specific compounds that are useful in treating diseases and disorders associated with mTOR. The pharmaceutical compositions derived from this work have the potential to significantly impact medical treatments. Additionally, she has introduced compounds such as 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H-1,3,6,9-tetraaza-fluorenes, which act as inhibitors of Checkpoint Kinase 1 (CHK1) function. This work not only explores the theoretical aspects of these compounds but also their application in treating proliferative conditions like cancer.

Career Highlights

Throughout her career, Jane has collaborated with notable companies such as Cancer Research Technology Limited and Cellzome Limited. Her role in these organizations highlights her expertise and commitment to advancing therapeutic research and development.

Collaborations

Jane has worked alongside esteemed colleagues including Ian James Collins and John Charles Reader, contributing to a collaborative environment that fosters innovation and success in pharmaceutical advancements.

Conclusion

Jane Elizabeth Scanlon's work exemplifies the importance of innovation in the field of medicine. Her patents not only enhance our understanding of complex biological systems but also pave the way for developing effective treatments for myriad health conditions. As she continues her work, her contributions will undoubtedly leave a lasting impact on the world of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.